Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteinase-activated receptor 2 (PAR-2), encoded by the F2RL1 gene, is a class A G protein-coupled receptor (GPCR) that plays a critical role in inflammation, pain, and cancer. Unlike typical GPCRs that are activated by soluble ligands, PAR-2 is activated through proteolytic cleavage of its extracellular N-terminus by serine proteases such as trypsin, mast cell tryptase, and coagulation factors VIIa and Xa. This cleavage exposes a tethered ligand sequence (SLIGKV in humans) that binds intramolecularly to activate downstream G-protein (Gq/11, Gi, G12/13) and beta-arrestin signaling pathways. PAR-2 is widely expressed in epithelial cells, endothelial cells, immune cells, and neurons, where it modulates inflammatory responses, vascular tone, and nociception. In disease states, PAR-2 is frequently upregulated and contributes to chronic inflammatory conditions (such as atopic dermatitis, asthma, and inflammatory bowel disease), neuropathic and migraine pain, and tumor progression and metastasis in various cancers. Consequently, PAR-2 has emerged as a highly attractive therapeutic target, with several monoclonal antibodies (e.g., MEDI0618) and small-molecule negative allosteric modulators (e.g., DT-9046) undergoing clinical and preclinical evaluation to block its activation and alleviate inflammation and pain.
Antagonism (including negative allosteric modulation and monoclonal antibody blockade) to inhibit protease-mediated cleavage and subsequent activation of downstream G-protein and beta-arrestin signaling pathways; or agonism to stimulate these pathways.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteinase-activated receptor 2 (PAR-2).